Very low frequencies of Toll-like receptor 2 supposed-2029T and 2258A (RS5743708) mutant alleles in southern Brazilian critically ill patients: would it be a lack of worldwide-accepted clinical applications of Toll-like receptor 2 variants?

Toll-like receptor 2 (TLR2) is a recognition receptor for the widest repertoire of pathogen-associated molecular patterns. Two polymorphisms of TLR2 could be linked to reduced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation and to increased risk of infection (suppos...

Full description

Saved in:

Bibliographic Details
Published in:	Genetic testing and molecular biomarkers Vol. 14; no. 3; p. 405
Main Authors:	Thurow, Helena Strelow, Sarturi, Cladinara Roberts, Fallavena, Paulo Roberto Vargas, Paludo, Francis Jackson de Oliveira, Picanço, Juliane Bentes, Fraga, Lucas Rosa, Graebin, Pietra, de Souza, Vinícius Carolino, Dias, Fernando Suparregui, Nóbrega, Otávio de Tolêdo, Alho, Clarice Sampaio
Format:	Journal Article
Language:	English
Published:	United States 01-06-2010
Subjects:	Adult Aged Alleles Brazil Communicable Diseases - complications Communicable Diseases - genetics Critical Illness Female Gene Frequency Genetic Markers Genetic Variation Genotype Humans Male Middle Aged Mutation Phenotype Polymorphism, Single Nucleotide Sepsis - etiology Sepsis - genetics Toll-Like Receptor 2 - genetics Brazil
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Toll-like receptor 2 (TLR2) is a recognition receptor for the widest repertoire of pathogen-associated molecular patterns. Two polymorphisms of TLR2 could be linked to reduced nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation and to increased risk of infection (supposed-2029C>T and 2258G>A). We investigated the supposed-2029C>T and 2258G>A TLR2 polymorphisms in 422 critically ill patients of European origin from southern Brazil (295 with sepsis and 127 without sepsis) and reviewed 33 studies on these polymorphisms, conducting a quality assessment with a score system. Among our patients we found only one heterozygote (1/422) for the supposed-2029C>T and none for the 2258G>A (0/422) single nucleotide polymorphism (SNP). We were unable to find a clinical application of supposed-2029T and 2258A allele analyses in our southern Brazilian population. Our review detected that current TLR2 SNP assays had very controversial and contradictory results derived from reports with a variety of investigation quality criteria. We suggest that, if analyzed alone, the supposed-2029C>T and 2258G>A TLR2 SNP are not good candidates for genetic markers in studies that search for direct or indirect clinical applications between genotype and phenotype. Future efforts to improve the knowledge and to provide other simultaneous genetic markers might reveal a more effective TLR2 effect on the susceptibility to infectious diseases.
ISSN:	1945-0257
DOI:	10.1089/gtmb.2009.0169